Patents by Inventor Cécile Mannioui

Cécile Mannioui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11603539
    Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: March 14, 2023
    Assignee: CELLECTIS
    Inventors: Roman Galetto, Agnès Gouble, Stéphanie Grosse, Cécile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
  • Publication number: 20150017136
    Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 15, 2015
    Applicant: CELLECTIS
    Inventors: ROMAN GALETTO, AGNÈS GOUBLE, STÉPHANIE GROSSE, CÉCILE MANNIOUI, LAURENT POIROT, ANDREW SCHARENBERG, JULIANNE SMITH
  • Publication number: 20130315884
    Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Application
    Filed: May 13, 2013
    Publication date: November 28, 2013
    Inventors: Roman Galetto, Agnès Gouble, Stéphanie Grosse, Cécile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith